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Abstract
Tricuspid valve regurgitation is one of the most common valvular disorders and 
moderate to severe tricuspid regurgitation is consistently associated to an increased 
morbidity and mortality. From an etiopathological perspective, tricuspid regur-
gitation can be classified in primary, due to the organic disease of any of the valve 
components, or secondary, as a result of tricuspid valve annulus dilatation, adverse 
right ventricular remodeling and tricuspid valve leaflet tethering. Despite its poor 
prognosis, most patients with tricuspid insufficiency are managed conservatively 
and only those with concomitant left heart valvular disease do finally go surgery in 
the real-world setting. In fact, outcomes of conventional surgery in patients with 
isolated tricuspid regurgitation are poor and this approach has not proven yet any 
survival benefit over stand-alone medical therapy. Given this unmet need, new 
transcatheter techniques have been developed in the last years, including leaflet 
plication, percutaneous annuloplasty and valve implantation in either the tricuspid 
position (orthotopic implantation) or in a different position such as the vena cava 
(heterotopic implantation). These techniques, with promising outcomes, are seen 
as an interesting alternative to open-heart surgery given the much lower periproce-
dural risk.
Keywords: percutaneous tricuspid valve repair, transcatheter tricuspid valve 
replacement, tricuspid valve insufficiency, tricuspid regurgitation, tricuspid valve
1. Introduction
Moderate or severe tricuspid regurgitation (TR) is a common disorder affecting 
over 1.6 million people in the United States and close to 70 million worldwide [1, 2]. 
In the vast majority of cases, the underlying mechanism is functional, due to right 
ventricular (RV) remodeling in patients with left-side heart disease, atrial fibrilla-
tion, primary pulmonary hypertension (PH) or RV dysfunction [3]. Although TR 
has been traditionally considered to be a benign valve disorder in comparison with 
left valve disease, it is conversely associated to a poorer prognosis. Furthermore, this 
finding has been consistently reported in different clinical scenarios, even in the 
absence of PH or right-side heart failure (HF) [4, 5]. However, most patients with 
significant TR only receive medical treatment and very few undergo invasive surgical 
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approach if no concomitant coronary or left valvular disease is present [6]. Thus, 
surgical tricuspid valve (TV) repair or replacement in isolated TR is fairly indicated 
and reported periprocedural mortality can be as high as 20% [7, 8]. Recently, new 
percutaneous techniques have shown promising results for the treatment of TR and 
appear as an alternative to conventional surgery in those cases where only conserva-
tive management could be offered in the past due to high surgical risk. In this chapter 
we will review the different devices that are currently available and to date published 
evidence for these approaches.
2. Tricuspid regurgitation
2.1 Anatomy of the tricuspid valve
The TV is a complex structure composed of three leaflets (septal, anterior and 
posterior), a fibrous TV annulus (TVA) in which these leaflets are inserted, at least 
two papillary muscles with multiple tendinous cords and the adjacent atrial and RV 
myocardium. Despite these general considerations, anatomical interindividual vari-
ability is high, and it is not so rare to find four or even five TV leaflets instead of three 
[9–11]. The anterior leaflet is usually more prominent and extends from the infun-
dibular region to the inferolateral wall. The posterior leaflet is smaller and, in some 
cases, hypoplastic, and it is inserted along the posterior margin of the TVA from the 
septum to the inferolateral basal segment. Lastly, the septal leaflet is fixed along the 
interventricular septum from the infundibulum to the posterior ventricular margin.
The fibrous TVA is not a flat structure but elliptic in shape under normal 
preloading conditions, with the posterolateral portion at a lower or more apical 
position and the anteroseptal portion in a higher or more atrial situation. Like the 
mitral valve annulus, the TVA is dynamic and changes shape and size during the 
cardiac cycle. TV is the largest and the most apically positioned heart valve, and can 
measure up to 9 cm2 in size in healthy subjects.
The subvalvular apparatus is composed of the tendinous cords and the papillary 
muscles. Usually, there are two different papillary muscles, anterior and posterior, 
but not infrequently, a third septal papillary muscle can be found. The anterior pap-
illary muscle is the largest of these muscles and gives rise to cords that sustain the 
anterior and posterior leaflets, while the posterior papillary muscle supports mainly 
the posterior and the septal leaflets. The septal leaflet is normally directly fixed 
to the septal ventricular wall by third order tendinous cords, resulting in reduced 
displacement during the cardiac cycle.
From an interventional perspective, some issues should be highlighted that may 
pose technical difficulties for an invasive approach [12–14]:
• The TV has a close anatomical relationship with other structures such as the 
non-coronary sinus of Valsalva (adjacent to the anteroseptal commissure), the 
atrioventricular node and the bundle of His (along the intramembranous portion 
of the septum) or the right coronary artery (which runs parallelly to the TVA).
• The distance between the outfall of inferior vena cava, the most frequent 
access for percutaneous TV intervention, and the TV is small, and this can 
challenge the achievement of coaxiality with the TV coaptation plane.
• Implantable cardiac devices can be frequently found in patients with TR and, 
even if not related to the mechanism of TR, right atrial and RV leads can dif-
ficult an adequate percutaneous approach.
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• The anterior position of the tricuspid valve significantly impairs echocardio-
graphic window by transesophageal echocardiography, which has become 
the main imaging technique for guiding structural and valve transcatheter 
interventions.
• Severe RV remodeling and systemic congestion can lead to huge dilatation 
of TVA and tethering of TV leaflets causing very wide gaps, which can limit 
reliable TV percutaneous intervention.
2.2 Etiology
Competence of the TV depends on the integrity of all its components (leaflets, 
TVA and subvalvular apparatus). The dysfunction of any of these structures can 
cause TR and we can differentiate two types according to the mechanism of the 
valve insufficiency:
a. Primary (10–20%): due to organic disease affecting mainly the TV leaflets and/
or the subvalvular apparatus (Table 1). This heterogeneous group includes 
congenital diseases, systemic and local inflammatory or infiltrative disorders, 
and traumatic damage of the valve [15].
b. Functional (80–90%): this is by far the most common type of TR and it is 
secondary to any of the following diseases [16–18]:
 ○ Left-side HF with either preserve or not preserve left ventricular ejection 
fraction: ischemic heart disease, hypertension, dilated cardiomyopathy, 
mitral or aortic valvular disease… leading to increased left atrial pressure and 
postcapillary PH.
 ○ Precapillary PH and/or primary RV dysfunction.
 ○ Atrial fibrillation (AF).
From a physiopathological perspective, all these disorders are closely related 
to each other and frequently two or more of them can coexist in the same patient. 
In fact, all of them end in a common pathway characterized by progressive TVA 
dilatation, RV dilatation and dysfunction, and TV leaflet tethering. These changes 
increase the TR regurgitation, thus, worsening RV adverse remodeling that further 
impairs the coaptation gap of TV leaflets [19]. Moreover, systemic congestion and 
Congenital Ebstein anomaly






Traumatism (blunt chest trauma)
Iatrogenic (ICD leads, EMD, drugs, radiation, surgery)
Table 1. 
Causes of primary tricuspid regurgitation. CHD: congenital heart disease, ICD: implantable cardiac devices; 
EMB: endomyocardial biopsy.
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chronic neuro-hormonal activation also contribute to this self-perpetuating mecha-
nism that, if untreated, conducts to irreversible end-stage right HF.
2.3 Diagnosis
To date, transthoracic echocardiography is the gold standard for diagnosis of TR. 
Current guidelines highlight the importance of a comprehensive evaluation of the 
TV in order to improve the quality of the diagnosis, but also, the decision-making 
process, including [20]:
a. TR severy: qualitative, semi-quantitative and quantitative parameters should 
support the grading of TR.
b. Etiology: primary vs. functional.
c. Mechanism: TVA dilatation, TV leaflet tethering, organic TV disease.
d. Complementary key information:
• Left heart size, function and valve disease.
• Pulmonary artery pressure (PAP).
• RV size and function: tricuspid annular plane systolic excursion (TAPSE), 2D 
longitudinal strain, RV-PA coupling).
• Fluid status (size of inferior vena cava).
It should be noted that most of these measurements can be significantly 
affected by the preload conditions of the patient at the time the study is per-
formed. Therefore, intensive intravenous diuretic therapy should be considered in 
patients with an over-volume status in order to perform the study in an as close to 
euvolemic state as possible. In this regard, vena contracta width is becoming one 
of the most used parameters for TR severy grading given its higher independency 
from preload conditions. Recently, a 5-degree scheme for grading TR based on 
the vena contracta and the effective regurgitation orifice area has been suggested 
pointing out the prognosis addictive significance of massive or torrential TR in 
patients with huge regurgitant orifices compared to severe TR [21] (Table 2). In 
this regard, patients with massive or torrential TR showed a lower survival, higher 




Mild Moderate Severe Massive Torrential
VC (biplane) <3 mm 3-6.9 mm 7-13 mm 14-20 mm ≥ 21 mm
EROA (PISA) <20 mm2 20-39 mm2 40-59 mm2 60-79 mm2 ≥ 80 mm2
3D VCA or quantitative 
EROA
75-94 mm2 95-114 mm2 ≥ 115 mm2
Table 2. 
New classification for grading the severity of TR. VC: vena contracta; EROA: effective regurgitant orifice area; 
3D VCA: three-dimensional vena contracta área.
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In addition, right ventricular systolic function assessment is essential when 
evaluating TR. This has been traditionally addressed by the TAPSE and the frac-
tional area change (FAC). However, recently the RV free wall longitudinal strain 
(> −23%) has been proposed as an independent risk factor for all-cause mortality 
and incremental to TAPSE and FAC [23]. In addition, although 3D- echocardiogram 
could evaluate accurately the RV ejection fraction, cardiac magnetic resonance is 
still the gold standard method to assess the RV function and volumes.
Together with the development of new percutaneous techniques, advance 
imaging of TR is also growing, and this evolution will probably contribute to a 
better understanding of the anatomy and mechanism of this disease. To date, both, 
transthoracic and, more specifically, transesophageal echocardiography play a key 
role in the indication of intervention, the selection of candidates for each percu-
taneous or surgical technique, and as guidance for transcatheter procedures [24]. 
In the following years, probably the magnetic resonance imaging and computed 
tomography will provide further insights in this pathology. Furthermore, we expect 
that all the advances in the field of TV imaging will help to find the optimal timing 
for intervention, which nowadays is one of the major challenges of this disease.
2.4 Prognosis
Up to mild TR can be oftenly found in healthy individuals. Moreover, the 
prevalence of moderate to severe TR has increased in the last years and will prob-
ably continue to rise given the expected aging of worldwide population. To date, it 
is frequently associated with other cardiac disorders and can be found in around 
15–40% of patients with AF, HF or severe left-side heart valve disease. The pres-
ence of significant TR is associated to an increased mortality in different series 
and this negative impact on outcomes is related to the severity of the TV insuf-
ficiency. In a retrospective study including more than 5000 patients, the survival 
rates at one year were 92% in patients without TR and 90%, 79% and 64% in 
those with mild, moderate or severe TR, respectively [25]. Likewise, Chorin et al. 
analyzed over 33.000 echocardiograms performed in a 5-year period. In this large 
single center cohort, moderate [HR 1.15, 95% CI 1.02–1.3, p = 0.024] and severe 
TR (HR 1.43, 95% CI 1.08–1.88, p = 0.011) had a worse prognosis than those with 
no or minimal TR [26].
Topilsky et al. observed similar findings when analyzed a cohort of 353 patients 
with isolated TR [27]. They concluded that severe isolated TR was an independent 
predictor of all-cause mortality and found that an effective regurgitant orifice over 
40 mm2 was significantly related to a reduced survival independently of other 
characteristics. It should be highlighted that adverse prognosis impact of moderate 
or severe TR has been reported in a wide range of diverse clinical scenarios, such as 
HF with either preserved or reduced left ventricular ejection fraction, atrial fibril-
lation without left-side HF or mitral or aortic valve disease. Interestingly, a recent 
meta-analysis including 70 studies and 32601 patients followed during a mean of 
over 3 years reported that moderate or severe TR was associated with a two-fold 
increased mortality risk compared to mild or no TR (RR 1.95, 95% CI 1.75–2.17) 
[4]. This association remained statistically significant when adjusted for systolic 
pulmonary artery pressure, RV dysfunction, left ventricular ejection fraction, AF 
or grade of mitral regurgitation.
2.5 Surgical approach
Several surgical approaches to treat TR have been suggested in the last decades. 
Among them, TV repair has been related to superior outcomes compared to TV 
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replacement [28]. Furthermore, ring annuloplasty offers a consistent reduction 
in TR in long-term follow up and is nowadays the first line technique in the TV 
anatomy is suitable [29].
Despite the increasing prevalence of significant TR and its adverse prognosis 
impact on survival, evidence to date of clinical benefit of open-heart surgery is 
scarse. Current guidelines in Europe and USA showed a consensual indication for 
symptomatic primary TR despite medical therapy and for functional TR in patients 
undergoing left heart valve disease. However, these recommendations have a C level 
of evidence.
On the contrary, the indication of TV surgery in patients with isolated func-
tional TR is still controversial. Some aspects should be highlighted regarding this 
issue. First, functional TR is a heterogeneous group including patients at very 
different stages of TV disease, PH and RV remodeling/function, which might not 
benefit from the same therapeutical approach. Second, the evaluation of clini-
cal status and its impairment related to TR is oftenly challenging, especially in 
elderly patients or those with comorbidities. Third, to date, TV surgery has not 
proven any benefit in hard outcomes compared to conservative management in 
this population. In this regard, Axtell et al. assessed outcomes in a retrospective 
cohort of 3276 patients with isolated TR. In this study, there were no differences in 
survival between patients who received medical versus surgical therapy (HR: 1.34; 
95% CI 0.78–2.30; p = 0.288). And four, reported outcomes of isolated TV surgery 
are poor. Alqahtani et al. recently reviewed trends and outcomes of isolated TV 
surgery in USA during over a decade [8]. They concluded that isolated repair was 
associated with high in-hospital mortality (8.1%) and significant rates of perma-
nent pacemaker implantation (10.9%) and new dialysis (4.4%). Morbidity and 
mortality were even worse among those patients who underwent TV replacement 
(10.9%, 34.1% and 5.5%, respectively). Similarly, Dreyfus reported an in-hospital 
mortality of 10% and 19% of major complications during admission in a series of 
241 patients who underwent isolated TV surgery in France during a 2 years period 
[30]. Authors suggested that patients are oftenly referred to late to surgery and that 
an earlier intervention may improve immediate and possibly midterm outcomes. 
Nevertheless, this hypothesis has not been proved yet. As a result, in the real-world 
setting, TV surgery for isolated TR is rarely performed and therefore, most patients 
are managed conservatively.
3. Transcatheter therapies for tricuspid regurgitation
Given the unmet need for invasive correction of TR with an assumable pro-
cedural risk, different percutaneous devices have been developed in recent years 
based on previous surgical techniques and percutaneous devices dedicated for the 
treatment of left-side valve disease. Table 3 summarizes anatomical target and 
surgical background, if any, of current available devices for transcatheter treatment 
of TR, including percutaneous TV repair (PTVR) techniques and orthotopic and 
heterotopic transcatheter TV valve implantation (TTVI). To date, only 3 devices 
have already obtain the CE mark for clinical practice [12, 31].
3.1 Percutaneous tricuspid valve repair
3.1.1 Percutaneous coaptation devices
These devices are designed to ultimately minimize the coaptation gap, including: 
1) MITRACLIP in the tricuspid position or TRICLIP that approximate the leaflets 
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increasing its coaptation surface; 2) FORMA device, comprising a spacer that 
occupies the regurgitant orifice; 3) PASCAL, that combines clipping of leaflets with 
a minor spacer; and 4) the MISTRAL device that approaches leaflets’ coaptation 
edge by stretching the subvalvular apparatus (Figure 1).
a. MITRACLIP/TRICLIP
MitraClip (Abbott Vascular, Santa Clara, CA, USA) is a polyester-coated 
chromium-cobalt device with two arms that open and close in a controlled 
manner through the release system. The device can be repositioned and more 
devices can be implanted until an adequate reduction of the valve insufficiency 
is achieved. This device was initially designed for the percutaneous treatment 
of mitral regurgitation and has already been used in over 100.000 for this 
purpose. With this back up of experience gained in the treatment of mitral 
regurgitation, it began to be used as an off-label therapy for TR and become the 
most widely used PTVR device (70% of all procedures).
The TriValve registry evaluated the results of MitraClip at 1-year follow-up in a 
series of 249 patients with TR [32]. Concomitant treatment of the mitral valve 
was carried out in 52% of the cases and two or more clips were implanted in 
69.1% of the patients received, most of them (65%) at the anteroseptal com-
missure (65%). Procedural success, defined as TR reduction to grade ≤ 2+, was 
achieved in 77% of cases and an improvement in functional class to NYHA ≤ II 





















MIA Suture annuloplasty No
TRAIPTA No No
NAVIGATE Tricuspid valve TVR No
LUX-VALVE TVR No
TRISOL VALVE TVR No




Transcatheter therapies for tricuspid regurgitation.
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was observed in 69% of patients. The following factors were identified as inde-
pendent predictors for procedural failure: tenting area > 3.15 cm2, non-central 
jet, regurgitation through the anteroposterior or posteroseptal commissure, 
coaptation gap >6.5 mm and regurgitant area > 0.695 cm2.
From a technical point of view, two approaches have been described for re-
ducing TR with MitraClip: the triple-orifice technique in which the clips are 
positioned centrally between the septal and the anterior leaflets, as well as be-
tween the septal and the posterior leaflets; and the bicuspidization procedure 
in which clips are deployed between the anterior and the septal leaflets [33] 
(Figure 2). Clipping of the anteroposterior commissure can be challenging 
and, sometimes, this may distort the valve and worsen TR [34].
The TriClip (Abbott Vascular, Santa Clara, CA, USA) is a dedicated MitraClip 
device for the TV. The prospective single-arm multicenter TRILUMINATE 
study evaluated the safety and feasibility of this system for treating TR. The 
6-month results involving 85 patients have recently been published [35]. 
Patients with severe PH or relevant mitral valve insufficiency were excluded. 
Technical success was achieved in all the patients and most clips were deployed 
between the anterior and septal leaflets (77%) with a reduction of at least one 
grade in the severity of TR in 91% of the cases. At 6-month follow-up, 86% 
of the patients presented moderate or less TR and were in NYHA functional 
class was I-II, and a significant improvement in the 6-minute walking test was 
observed.
Figure 1. 
Tricuspid coaptation devices. A: TRICLIP, B: PASCAL, C: FORMA, D: MISTRAL.
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Patients with significant TR and implantable cardiac devices represent a par-
ticularly challenging population. In a cohort of the TriValve registry, PTVR 
was performed in 121 patients with an intracardiac RV electrodes. Most of 
these patients, 106 (87%), were treated with MitraClip and compare to those 
without intracardiac devices, no significant differences were documented in 
procedural success, TR reduction (TR ≤ 2+ 73.7% vs. 70.8%, p = 0.6), clinical 
improvement or survival [36].
b. PASCAL
The Pascal system combines the possibility of grasping the leaflets as with the 
MitraClip device with the use of a spacer. This affords improved coaptation 
and better outcomes following percutaneous repair of TR. The first experience 
targeted to the tricuspid valve in humans have recently been published [37]. 
Out of 28 patients (98% with functional TR), the procedure success rate was 
86%, with no complications in any case. Forty devices were implanted - mostly 
in the anteroseptal position (70%). Detachment of the device was recorded in 
two patients, and 85% of the subjects presented TR ≤ 2+ after 30 days.
Although no clinical trials have compared any of these therapies versus pla-
cebo in patients with TR, an observational study has compared the use of the 
MitraClip with the PASCAL system in the treatment of this valve disease. In 
Figure 2. 
A: Percutaneous tricuspid valve repair with MitraClip. B: Triple-orifice technique. C: Bicuspidization aproach.
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this study published by Braun et al., in which 88 patients were treated with the 
MitraClip and 32 received the PASCAL system, no differences were observed 
between the two devices in terms of success of the procedure, the reduction of 
TR or detachment of the device (11% with MitraClip versus 6% with PAS-
CAL). The authors concluded that both devices are similar in terms of efficacy 
and safety in reducing TR [38].
c. FORMA
The FORMA system (Edwards Lifesciences, Irvine, CA, USA) is designed to 
increase leaflet coaptation, occupying the regurgitant orifice with a spacer 
[39]. A guide is advanced through the subclavian or axillary vein and anchored 
in the apex of the right ventricle. The spacer is then advanced to the tricuspid 
valve plane. Finally, the excess guide is implanted in a subcutaneous pouch. 
The results after 2–3 years of the first cohort of 19 patients treated with this 
system have recently been published [40]. The procedure proved successful in 
89% of the patients, with the recording of one case of right ventricle perfora-
tion. After four months another patient suffered thrombosis of the device, and 
pulmonary thromboembolism was also evidenced in another subject. Although 
functional class improvement was observed in 93% of the cases, at last follow-
up only one-third of the patients presented moderate or lesser TR. The FORMA 
early feasibility study reported two right ventricle perforations in the cohort of 
29 patients. A decrease in TR was seen in 49% of the cases [40]. Despite these 
outcomes, most of the patients experienced improvement of their functional 
class. The single-arm SPACER trial is currently ongoing and will evaluate mor-
tality after 30 days with this device.
d. MISTRAL
The results of the first experience in humans with the Mistral device (Mitralix, 
Yokneam, Israel) have recently been published [41]. This device consists of a 
spiral nitinol guide that grasps the tendinous cords, approximating them to 
the leaflets and thus increasing coaptation. This study included 7 patients with 
severe functional TR; one of them required two devices. No adverse events 
related to the procedure were recorded after 30 days, and a significant decrease 
in effective regurgitant orifice area (EROA), vena contracta and regurgitant 
volume was achieved, together with improved functional class.
3.1.2 Percutaneous annuloplasty devices
As it has been explained above, the basic mechanism underlying functional TR 
is TVA dilatation, which mainly occurs in its anteroseptal diameter. TV annulo-
plasty is currently the surgical treatment of choice in this scenario. Based on this 
surgical technique, different percutaneous annuloplasty devices have been devel-
oped in recent years with the fundamental aim of reducing the annular dimensions 
and prevent further TVA dilatation. These devices can be classified into rings 
(CARDIOBAND, IRIS MILLIPEDE, DA VIGNI, TRAIPTA) or direct suture devices 
(TRIALIGN, TRICINCH, PASTA, MIA) (Figure 3).
a. CARDIOBAND
The CARDIOBAND (Edwards Lifesciences, Irvine, CA, USA) is an annulo-
plasty system consisting of an adjustable surgical-like Dacron ring that is im-
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planted on the atrial side of the tricuspid TVA and fixed with multiple anchors. 
Once the last anchoring has been placed, the device is cinched until enough 
TR reduction is achieved. The two-year results of the TRI-REPAIR study have 
recently been published. This trial evaluated the efficacy and safety of this sys-
tem in 30 patients with symptomatic functional TR (83% in NYHA functional 
class III-IV) [42]. The procedure was successful in all patients and related to 
a significant reduction in TR (72% of the subjects presented TR ≤ moderate) 
and TVA dimension, and to an improvement in functional status (82% of the 
subjects were in NYHA class I-II), 6-minute walk distance and quality of life at 
24-months follow-up. The Early Feasibility Study of CARDIOBAND included 
22 patients with severe symptomatic TR in which this treatment was carried 
out [43]. The procedure success rate was 96%, with improvement of both the 
severity of TR and of the NYHA functional class.
b. IRIS MILLIPEDE
The IRIS transcatheter annuloplasty system (Boston Scientific, Marlborough, 
MA), is a complete semirigid ring that is placed in a supra-annular position 
and anchored through 7–9 screws. The ring can be adjusted to reduce the 
Figure 3. 
A: CARDIOBAND, B: Iris MILLIPEDE, C: TRIALIGN, D: TRICINCH, E: Pasta, F: TRAIPTA, G: Mia.
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TVA diameter and thus the severity of TR. Although this system was initially 
designed to be used in the mitral valve, Rogers et al. presented the results 
obtained in two patients that received this device in the tricuspid position 
in a combined procedure with the mitral valve annuloplasty [44]. For the 
TV treatment, only 7 of the 9 anchors were used in order to avoid the risk of 
atrioventricular block. The results in these patients were good showed no need 
for a pacemaker and a 40% reduction of the TVA size after 12 months, with no 
residual significant TR.
c. DA VINGI
The DA VINGI is a percutaneous annuloplasty device designed to treat the 
mitral and tricuspid valves. This device allows complete annuloplasty with a 
single-step implant. Following a healing period (90 days), the ring is adjusted 
percutaneously. The device has been successfully implanted to date in 6 pa-
tients [45].
d. TRIALING
The TRIALING (Mitralign Inc., Tewksbury, MA, USA) is a direct suture device 
that reproduces the Kay tricuspid bicuspidization surgical technique leading 
to the obliteration of the posterior leaflet of the TV. Through a transjugular 
percutaneous access, two pledgets are inserted in the anteroposterior and pos-
teroseptal commissures. The pledgets are then approximated with a cinching 
mechanism, bringing both commissures together and obliterating the posteri-
or leaflet. The first published experience corresponds to 14 patients with mod-
erate to severe functional TR, achieving a 51% decrease in EROA and a 34% 
reduction of the TVA area [46]. The early feasibility SCOUT I trial included 15 
patients with functional TR and the device was successfully implanted in all 
patients [47]. One patient required right coronary angioplasty due to extrinsic 
compression. At 30-days follow-up, 3 single-pledget annular detachment were 
documented without reintervention. In the remaining 12 cases, a significant 
reduction in the TVA area and EROA were observed, together with clinical 
improvement in functional status [47]. After 12 months, only one patient 
required surgery. The SCOUT II study is currently ongoing and will include 60 
patients [48].
e. TRICINCH
The TriCinch (4Tech Cardio, Galway, Ireland) is an annuloplasty system that 
consists of a screw for anchoring to the TVA at its supravalvular anterior area 
and a Dacron band attached to an expandable stent that is placed at the in-
ferior vena cava (IVC), generating tension and thus reducing the diameter 
of the septolateral diameter of the TVA. In the PREVENT study, 24 patients 
were treated with the first generation of this device. Implantation success was 
achieved in 81% of the patients, with a reduction of one grade or more in the 
severity of TR in 94% of the cases, together with functional class improve-
ment. However, two patients suffered hemopericardium and 5 late detach-
ments were recorded. Because of this, the second-generation TriCinch was 
developed, incorporating an improved anchoring coil system that is inserted in 
the pericardial space with two hemostatic seals. The first in-human experience 
suggests that the device is safe.
13
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f. PASTA
Lastly, the Pledget-assisted suture tricuspid annuloplasty (PASTA) device is 
an annuloplasty system that reproduces Hetzer’s double orifice suture tech-
nique. Two sutures are placed at ring level in its anterolateral and posterosep-
tal portion, with tightening and approximation of the extremities, creating 
a tricuspid valve with two orifices similar to the final outcome obtained after 
percutaneous mitral valve repair with the MitraClip device. The first experi-
ence was obtained in a porcine model, with good results [49]. The first experi-
ence in humans has recently been published, evidencing a marked reduction in 
valve area - though dehiscence of the device occurred after two days, with the 
recurrence of TR [50].
g. MIA
The Minimally Invasive Annuloplasty (MIA, Micro Interventional Devices, 
Newtown, PA, USA) system is a sutureless device with two anchorages that 
allow reduction of the tricuspid ring. The STTAR study will include 40 patients 
and will evaluate the efficacy and safety of this device [51].
h. TRAIPTA
The transatrial intrapericardial tricuspid annuloplasty (TRAIPTA) system is an 
external indirect annuloplasty device. It consists of an adjustable nitinol guide 
that is advanced through the inferior vena cava to the atrium and penetrating 
the pericardium through a puncture in the right appendage. Once within the 
pericardial space, it is positioned in the atrioventricular sulcus, adjusting its 
size and thus reducing the diameter of the tricuspid ring and improving coap-
tation of the leaflets. The first experience was with a porcine model, in which a 
decrease in TR was achieved, with improvement of coaptation and reduction 
of the diameter of the ring, without serious complications [52]. The puncture 
zone was sealed with an atrial septal occluder (Amplatzer, St. Jude Medical, 
St. Paul, Minnesota or Lepu Medical, Beijing, China) in all cases. Although no 
results in humans are yet available, a new version of the device will be evalu-
ated in a feasibility trial in the coming years.
3.2 Percutaneous tricuspid valve replacement
3.2.1 Orthotopic tricuspid valve implantation
Orthotopic TTVI implies TV replacement and the prosthesis is anchored to the 
native ring and leaflets. To date, there are three devices available: GATE, LUX-
VALVE, TRISOL and EVOQUE (Figure 4A-C).
a. GATE
The GATE (NaviGate Cardiac Structures, Lake Forest, CA, USA) is a self-ex-
panding valve dedicated for placement in the tricuspid position. This is a coni-
cal shaped device with three pericardial leaflets surrounded by a nitinol stent 
that has twelve atrial winglets and ventricular graspers to ensure anchoring. The 
device comes in 5 different sizes (36, 40, 44, 48 and 52 mm in diameter) and 
the procedure can be performed via transjugular or through a minithoracot-
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omy access. The first reported compassionate use of this system in 35 patients 
recorded a procedural success rate of 76%, with residual TR ≤ 2+ in all cases, 
and need for surgery in 14% with a 14% 30-day mortality [53]. A multicenter 
registry has been recently published including 30 patients with severe TR and 
right ventricular dysfunction in which the GATE system [54]. Technical success 
was achieved in 87%, but device malpositioning occurred in 4 patients, with 
conversion to open heart surgery in 2 of them (5%). Among those who received 
the device, 76% had mild or less TR at discharge with an in-hospital mortal-
ity was 10%. In addition, at 6-months follow-up, 62% of the patients were in 
NYHA I or II with no late device-related adverse events were documented.
b. LUX-VALVE
LUX-Valve (Jenscare Biotechnology, Ningbo, China) is a self-expanding valve 
that is inserted through the right atrium via a minithoracotomy and anchored 
throught a dedicated mechanism to the leaflets and the interventricular sep-
tum. Lu et al. published their first-in-human experience in 12 patients with 
severe TR and functional class IV [55]. The procedure was successful in all 
patients, but one patient required surgery due to bleeding and another died 
of an acute myocardial infarction. A decrease in TR was observed in all cases, 
with only one of them with a residual moderate leak. The largest series to date 
with results from 35 patients with severe TR and functional class III/IV has 
recently been communicated [56]. The mortality rate at 30 days was 5.7%, with 
significant clinical improvement in NYHA functional class and a decrease in 
right ventricle volume.
c. TRISOL
The TriSol (TriSol Medical, Yokneam, Israel) is a valve specifically designed for 
the treatment of TR that is still in the preclinical development phase.
Figure 4. 
A: Gate, B: Lux-valve, C: TRISOL, D: Edwards SAPIEN, E: TRICVALVE, F: TRICENTO.
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d. EVOQUE
The EVOQUE valve (Edwards Lifesciences, Irvine, CA) was recently evaluated 
in 25 symptomatic (96% NYHA III or IV) patients with severe TR. At 30 days 
76% of the patients were in NYHA I/II and 96% had a TR 2+ with a 92% of 
technical success [57].
3.2.2 Heterotopic tricuspid valve implantation
Heterotopic TTVI refers to the implantation of a competent valve in a position 
different from the native tricuspid valve. The inferior vena cava (IVC), generally 
in combination with the superior vena cava (SVC), are the sites of choice, leading 
to the ventricularization of the right atrium [17]. Therefore, this approach does not 
address the TR itself, but prevents from severe systemic venous congestion related 
to right HF. As a palliative therapy, is it usually indicated in severely symptomatic 
patients with end-stage HF and massive or torrential TR not deemed candidates 
for other invasive approaches. Compared with orthotopic TTVI, this procedure is 
simpler, avoids the introduction of prosthetic material in the inlet of the RV and the 
position of the valve does not interfere with pacemaker or defibrillator electrodes, 
if present [58]. On the contrary, clinical impact of untreated TR, right atrial ven-
tricularization, persistent right atrial volume overload and potentially increased 
RV afterload is unknown. This group of devices includes SAPIEN, TRICVALVE and 
TRICENTO (Figure 4D–F).
a. SAPIEN
The SAPIEN (Edwards Lifesciences, Irvine, CA, USA) is a triple-leaflet bovine 
pericardium valve initially designed for aortic valve replacement in patients 
with severe aortic stenosis. The first off-label use of the SAPIEN XT in the 
IVC was published in 2013 in three patients [59]. After that initial experience, 
this technique was tested in a randomized controlled trial that included 28 
patients comparing medical treatment versus percutaneous implantation of 
this valve in the IVC. The main endpoint of the trial was the exercise capacity 
evaluated by cardiopulmonary exercise test. Nevertheless, this study had to be 
suspended prematurely due to futility and to the recording of numerous com-
plications in the device group [60]. The analysis of available data evidenced a 
systolic decrease in the hepatic vein flow, without reverse RV remodeling [61]. 
In a recent retrospective multicenter registry enrolling 25 patients with severe 
symptomatic TR undergoing heterotopic TTVI (72% SAPIEN XT/3, 24% 
TRICVALVE and 4% DIRECTFLOW) in the IVC (76%) or both VC (24%), 
the procedure was successful in 96% of the patients although in-hospital mor-
tality was 16% [62].
b. TRICVALVE
The TRICVALVE (P&F Products & Features, Vienna, Austria) is a device spe-
cifically designed for its implantation in VC. It consists of two self-expanding 
bovine pericardium valves on a nitinol stent, one for each VC. Lauten et al. 
published first in-human experience in 2011 in a patient that showed clinical 
functional improvement after 8 weeks [63]. The TRICUS feasibility study is 
currently ongoing and will include 10 patients in order to evaluate of clinical 
and adverse events using this device [NCT03723239].
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c. TRICENTO
The Tricento (NVT, Muri, Switzerland) is a coated bicaval covered stent with a 
bicuspid valve positioned laterally that that allows inflow into the right atrium. 
Since the first experience reported in 2018 [64], isolated cases have been pub-
lished, with good periprocedural results [65, 66].
3.3 Outcomes after transcatheter tricuspid valve therapies
3.3.1 Clinical benefits
Most feasibility studies and observational registries have shown a significant 
clinical improvement in terms of NYHA functional class, quality of life or 6-minute 
walk test in patients undergoing PTVR or TTVI. These changes were observed 
even after conservative reductions of TR of 1 or 2 grades after PTVR. Nevertheless, 
no data are available from randomized controlled trials comparing percutaneous 
approach with medical management, and current reported follow-up does not 
exceed 1 or 2 years after the invasive procedure.
With regard to cardiovascular events, Orban et al. evaluated rates of admissions 
due to HF in 119 patients undergoing isolated PTVR (MitraClip 97%) comparing 
the year before and after the procedure [67]. PTVR was associated with a signifi-
cant reduction in the grade of TR to moderate or less in 72% of the cases and with a 
significant lesser incidence of HF admissions (p = 0.02).
Recently, results from the TriValve registry that included 312 patients mostly 
treated with MitraClip device, reported that 30-day mortality was significantly 
lower among those with procedural success (1.9% vs. 6.9%, p = 0.04) [68]. 
Furthermore, more recently, Taramasso et al. published a retrospective propensity 
matched case–control study that included 268 patients from the same registry who 
underwent PTVR and observed significant lower 1-year mortality (23 ± 3% vs. 
36 ± 3%, p = 0.001) and rehospitalization (26 ± 3% vs. 47 ± 3%, p < 0.0001) rates 
when compared to controls managed conservatively [69]. In addition, those patients 
treated with PTVR had higher survival after adjusted for sex, NYHA functional 
class, right ventricular dysfunction and AF. Although these results are encourag-
ing, potential survival benefit of transcatheter tricuspid valve interventions over 
stand-alone medical therapy needs to be tested in clinical trials. Currently, diverse 
ongoing randomized trials will assess this issue in patients receiving TriClip, Pascal, 
Cardioband, and other PTVR devices.
3.3.2 Predictors of outcomes
One of the major limitations of TV surgery is reported high periprocedural 
mortality. Despite transcatheter approaches seem to significantly reduce this risk, 
patient selection remains key to achieve optimal procedural and clinical results. In 
this regard, some important determinants of outcomes have ben already suggested:
a. PH and RV function: Lurz et al. evaluated invasive pulmonary artery pres-
sures and echocardiographic parameters in 243 patients who underwent 
PTVR [70]. The presence of invasive PH, defined as pulmonary artery systolic 
pressure > 50 mmHg), together with discordant absence of PH by echocardio-
graphic estimation, was associated with the combined primary endpoint of 
all-cause mortality, need for repeat hospitalization for HF and reintervention 
during follow-up. This could be explained because in advanced stages of TR 
associated with adverse RV remodeling with severe dilation of the TV annulus, 
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pulmonary hypertension may be severely underestimated by echocardiog-
raphy. Moreover, Stocker et al. observed in a multicenter study including 
236 patients that invasive mean pulmonary artery pressure, transpulmonary 
gradient, pulmonary vascular resistance and RV stroke work were significant 
predictors of 1-year mortality, and that patients with pre-capillary PH had 
the worse prognosis [71]. Similarly, the ratio between TAPSE/invasive PH 
<0.29 mm/mmHg has also shown adverse prognosis impact [72]. This finding 
points out the close relationship between the RV function and PH. So-called 
RV-PA coupling refers to the fact that RV contractility should “match” the RV 
afterload.
b. Nutritional status: from a clinical perspective, a recent study reported that 
an impaired nutritional status is also associated with an increased risk of 
death and rehospitalization for heart failure after PTVR [73]. This finding is 
important since to date most patients were referred to invasive management 
at an advance stage of RV failure in which nutritional status might be already 
impaired and this can impact outcomes.
3.3.3 Patient and device selection
The decision-making process for patient and device selection in these early 
stages of percutaneous approaches to treat TR prompts exhaustive clinical evalua-
tion, specifically guided right heart catheterization and transesophageal hemody-
namic and anatomical evaluation, and heart team meeting. Figure 5 summarizes a 
theorical approach.
Figure 5. 
Theorical algorithm for device selection. TTVI: Transcatheter tricuspid valve implantation, AP: Anteroseptal, 
PS: Posteroseptal, AP: Anteroposterior.
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4. Conclusions
TR is a common heart valve disease associated with high morbidity and mortal-
ity when conservatively managed. Surgery is currently the treatment of choice, 
though very few patients with isolated TR undergo TV surgery in the real-world 
setting due to high surgical risk. In recent years, different percutaneous treatment 
devices have been developed offering promising results with much lower procedural 
adverse outcomes. Further studies are needed to find which will benefit the most 
from these therapies.
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Appendices and Nomenclature
AF Atrial Fibrillation
CHD Congenital Heart Disease
EMB Endomyocardial biopsy
EROA Effective Regurgitant Orifice Area
FAC Fractional Area Change
ICD Implantable Cardiac Device
MIA Minimally Invasive Annuloplasty
PAP Pulmonary Artery Pressure
PASTA Pledget-assisted suture tricuspid annuloplasty
PH Pulmonary hypertension
PTVR Percutaneous Tricuspid Valve Repair
RV Right ventricle
TAPSE Tricuspid Annular Plane Systolic Excursion
TR Tricuspid Regurgitation
TRAIPTA Transatrial Intrapericardial Tricuspid Annuloplasty
TTVI Transcatheter Tricuspid Valve Implantation
TV Tricuspid valve
TVA Tricuspid Valve Annulus
VC vena contracta
3D VCA three-dimensional vena contracta área
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